Pan Cancer T

Today we have been celebrating our recent publication in Cancer Discovery! This paper introduces ROPN1 as a novel target for adoptive cell therapy and characterises the highly specific natural T cell receptor (TCR) that we are now developing into a TCR-T cell product for the treatment of triple negative breast cancer and melanoma.    Congratulations and thank you to all the team that have worked so hard to achieve this milestone, with special mention to the lead authors, Dian Kortleve and Dora Hammerl, and the PI, Reno Debets from Erasmus MC!

🚀 Today is a landmark day for TCR-T cell therapies! Adaptimmune’s #TECELRA® has made history as the first #TCRT cell product to receive FDA approval: https://t.ly/i3tf8 TECELRA is also the first #engineered #CellTherapy to be marketed for treatment of a #SolidCancer. 🙌 Fantastic news for patients with advanced MAGE-A4+ #SynovialSarcoma, a rare, soft tissue cancer that most commonly impacts young adults. TECELRA is the first new treatment option in more than a decade. 🎉 Huge congratulations to the dedicated team at Adaptimmune that have worked so hard to bring TECELRA to market! Our CEO Rachel Abbott was privileged to have contributed, even in a small way, to its preclinical development during her time at the company. 💡 The approval of TECELRA highlights the promising potential of TCR-T cell therapies and further motivates all of us at Pan Cancer T, as we work on developing next generation TCR-T cell therapies for other solid cancers, including triple negative breast cancer.

Pan Cancer T secures €4.25M seed extension round We are delighted to announce the successful closing of Pan Cancer T’s €4.25 million seed extension round, which will accelerate development of our next-generation T cell therapies. See press release: https://t.ly/CjFGq This financing round will enable us to advance our lead TCR-T cell product, PCT1:CO-STIM, to the clinic for the treatment of triple negative breast cancer, and support progression of earlier-stage pipeline projects. It also provides a firm foundation to secure a Series A round within the coming year and seek business development partnerships with Biotech and Pharma collaborators to further develop our assets (including our TCR:CO-STIM platform that is applicable to other TCRs and tumour indications). We would like to welcome our new investor, InnovationQuarter, and thank our existing investors, Van Herk Ventures (Van Herk Groep), Thuja Capital, Swanbridge Capital and Erasmus MC O&O Holdings, for their continued support.

Our CEO, Rachel Abbott, and co-founder, Dora Hammerl, enjoyed chatting with Rotterdam Square recently about the benefits of being part of the Rotterdam ecosystem, our recent grant funding and the progress we are making developing next generation TCR-T cell therapies for solid cancer including triple negative breast cancer.

Pan Cancer T's CEO, Rachel Abbott is looking forward to participating in the EIT Health #Catapult finals at health.tech conference in Munich tomorrow!

We are delighted to have been awarded this Dutch Cancer Society Public Private Partnership award, together with our co-founder Reno Debets, to help us develop next generation adoptive T cell products that are resistant to inhibitory macrophages in the hostile tumour microenvironment. #KWF #ErasmusMC #ErasmusMCCancerInstitute

The 5 minute pitch we presented as part of the EIT Health Catapult 2024 semi-finals is now available to watch online until 15th February. Follow the link if you would like to hear how Pan Cancer T is developing next generation T cell therapies to treat solid cancers, starting with Triple Negative Breast Cancer. https://lnkd.in/exGhN33z Find us in the Life Science category.